Skip to content

Atopic Dermatitis: Global and China Landscape

Atopic dermatitis treatment is moving into a new phase, where convenience, safety and access matter as much as efficacy.

  • Crowded Pipeline: China has one approved home-grown IL-4Rα antibody and seven more under regulatory review, making it a major hub of late-stage development.
  • New Differentiators: With few head-to-head trials to rank efficacy, longer dosing intervals, faster itch relief and lighter monitoring are increasingly what sets therapies apart.
  • Access Decides Uptake: National reimbursement listing (NRDL), provincial coverage and whether patients stay on treatment will shape real-world adoption.

See how ten targets compare, from IL-4Rα to OX40 and TYK2.

Download the Full Report

Get Your Selesta Report

1

Anytime Access

Praesent porttitor, nulla vitae posuere iaculis, arcu nisl dignissim dolor, a pretium mi sem ut ipsum. Fusce fermentum.

2

Add-ons Compatibility

Praesent porttitor, nulla vitae posuere iaculis, arcu nisl dignissim dolor, a pretium mi sem ut ipsum. Fusce 

×

Get Your Selesta Report